Breaking News Instant updates and real-time market news.

RDHL

RedHill Biopharma

$6.50

-0.26 (-3.85%)

09:04
10/11/19
10/11
09:04
10/11/19
09:04

RedHill Biopharma reports results from MAP US Phase 3 study of RHB-104

RedHill Biopharma announced full Week 52 results for all subjects in the previously announced Phase 3 randomized, controlled study of RHB-104 in Crohn's disease and supportive top-line results from the open-label extension Phase 3 study. The full Week 52 results of blinded treatment in the MAP US Phase 3 study with RHB-104 were consistent with the previously reported positive outcomes of the study. The study continued to meet its primary endpoint of clinical remission at week 26, key secondary endpoints of maintenance of remission at weeks 16 and 52 and, notably, durable clinical remission on all visits, week 16 through 52. In the analysis of the complete safety information for the study, a top-line electrocardiogram monitoring report for the MAP US study recently received and shared with FDA, demonstrated evidence of progressive prolongation of the QTcF interval across visits, with the largest placebo-correcteddQTcF of 30.6 ms at Week 52 of treatment with RHB-104. None of these QT abnormalities resulted in adverse cardiac events. Clofazimine, as well as clarithromycin, are known to be associated with QT prolongation. RedHill continues to analyze the data from the RHB-104 studies, including QT prolongation findings and various pharmacokinetic and pharmacodynamic models and, as previously announced, intends to meet with the FDA again in the coming months to discuss the RHB-104 program, including these data. The MAP US2 open-label extension Phase 3 study evaluated the safety and efficacy of RHB-104 in subjects from the MAP US study with persistent active Crohn's disease after 26 weeks of blinded study therapy. A total of 54 subjects entered the open-label extension study and 30 subjects completed 52 weeks of treatment. Interim top-line results from the MAP US2 study demonstrated 27.8% clinical remission with RHB-104 at week 16 and 22.2% remission at week 521. Of the MAP US2 subjects who were previously randomized to the placebo arm in the MAP US study and treated with RHB-104 for the first time in the MAP US2 study, 31.6% achieved remission at week 16 and 26.3% achieved remission at week 52. These results further support the potential clinical benefit of treatment with RHB-104 in Crohn's disease patients. RHB-104 was found to be generally safe and well tolerated. The incidence of treatment emergent adverse events, serious adverse events and reported adverse events leading to discontinuation in the MAP US2 study were lower than in the active arm of the MAP US study/ Similar trends were observed in MAP US2 subjects who received concomitant anti-TNFs, consistent with the safety of treatment with RHB-104 in combination with anti-TNF agents. The top-line results and subsequent analyses were provided to RedHill by an independent third party following an independent analysis and remain subject to completion of the independent review and analysis of the underlying data, including all safety, secondary and other outcome measures, and completion of the Clinical Study Report.

  • 02

    Nov

RDHL RedHill Biopharma
$6.50

-0.26 (-3.85%)

02/27/19
HCWC
02/27/19
NO CHANGE
Target $16
HCWC
Buy
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for RedHill Biopharma to $16 saying reliance on a potential partnership could reduce RHB-104's economic value. Based on management comments, the analyst believes RedHill will likely wait for a partnership before moving the RHB-104 program forward. However, Ramakanth still expects Talicia to be approved with a potential commercial launch in the U.S. by Q4. The analyst reiterates a Buy rating on the shares.
03/12/19
WBBS
03/12/19
UPGRADE
WBBS
Buy
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
03/12/19
03/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Electric (AEP) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company has filled out $1.4B of non-utility renewables investment and entered into an Oklahoma settlement that "bodes well for lag catch up" over the last two months. 2. Lloyds Banking (LYG) upgraded to Neutral from Sell at Goldman Sachs. 3. RedHill Biopharma (RDHL) upgraded to Buy from Hold at WBB Securities. 4. Eaton (ETN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Jeffrey Hammond saying he believes the stock has traded at an "unwarranted discount" to peers. 5. Ranger Energy (RNGR) upgraded to Overweight from Equal Weight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
WBBS
07/12/19
UPGRADE
WBBS
Strong Buy
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities

TODAY'S FREE FLY STORIES

SAP

SAP

$129.13

0.55 (0.43%)

05:41
10/21/19
10/21
05:41
10/21/19
05:41
Earnings
SAP continues to expect FY19 revenue to 'increase strongly' »

Backs FY19 non-IFRS cloud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

PBF

PBF Energy

$29.29

0.64 (2.23%)

05:39
10/21/19
10/21
05:39
10/21/19
05:39
Upgrade
PBF Energy rating change  »

PBF Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SAP

SAP

$129.13

0.55 (0.43%)

05:38
10/21/19
10/21
05:38
10/21/19
05:38
Earnings
SAP reports Q3 non-IFRS EPS EUR 1.30 vs. EUR 1.14 last year »

Reports Q3 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

DANOY

Danone

$0.00

(0.00%)

05:32
10/21/19
10/21
05:32
10/21/19
05:32
Downgrade
Danone rating change  »

Danone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JBAXY

Julius Baer

$0.00

(0.00%)

05:30
10/21/19
10/21
05:30
10/21/19
05:30
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$138.08

0.31 (0.23%)

05:28
10/21/19
10/21
05:28
10/21/19
05:28
Hot Stocks
Danaher to sell certain businesses to Sartorius AG for $750M »

Danaher announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

SAP

SAP

$129.13

0.55 (0.43%)

, MSFT

Microsoft

$137.34

-2.34 (-1.68%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Hot Stocks
SAP enters go-to-market partnership with Microsoft »

SAP (SAP) and Microsoft…

SAP

SAP

$129.13

0.55 (0.43%)

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

ALSMY

Alstom

$0.00

(0.00%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Downgrade
Alstom rating change  »

Alstom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$0.00

(0.00%)

05:25
10/21/19
10/21
05:25
10/21/19
05:25
Downgrade
Danone rating change  »

Danone downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$165.61

-1.87 (-1.12%)

05:24
10/21/19
10/21
05:24
10/21/19
05:24
Hot Stocks
Honeywell sees 7,600 new business jet deliveries over next decade »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

05:23
10/21/19
10/21
05:23
10/21/19
05:23
Downgrade
Boeing rating change  »

Boeing downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IRT

Independence Realty Trust

$15.03

(0.00%)

05:22
10/21/19
10/21
05:22
10/21/19
05:22
Downgrade
Independence Realty Trust rating change  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

RHHBY

Roche

$0.00

(0.00%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Hot Stocks
Genentech says Phase III IMbrave150 study met co-primary endpoints »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 12

    Nov

  • 07

    Dec

PINS

Pinterest

$25.30

-0.7 (-2.69%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

05:20
10/21/19
10/21
05:20
10/21/19
05:20
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

05:18
10/21/19
10/21
05:18
10/21/19
05:18
Recommendations
Micro Focus, OpenText analyst commentary  »

Micro Focus could attract…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

, CRM

Salesforce

$144.18

-1.995 (-1.36%)

05:15
10/21/19
10/21
05:15
10/21/19
05:15
Recommendations
Microsoft, Salesforce, Intuit, SailPoint, Zuora, Varonis analyst commentary  »

High growth software…

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

CRM

Salesforce

$144.18

-1.995 (-1.36%)

INTU

Intuit

$262.54

-4.03 (-1.51%)

SAIL

SailPoint

$18.32

-0.34 (-1.82%)

ZUO

Zuora

$13.63

-0.5 (-3.54%)

VRNS

Varonis

$62.36

-1.56 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 16

    Dec

XLRN

Acceleron

$42.16

-1.02 (-2.36%)

05:09
10/21/19
10/21
05:09
10/21/19
05:09
Recommendations
Acceleron analyst commentary  »

Piper sees near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

  • 04

    Apr

TLSNF

Telia

$0.00

(0.00%)

05:04
10/21/19
10/21
05:04
10/21/19
05:04
Downgrade
Telia rating change  »

Telia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALRM

Alarm.com

$47.23

-0.5 (-1.05%)

05:01
10/21/19
10/21
05:01
10/21/19
05:01
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

  • 09

    Dec

SWAV

ShockWave Medical

$32.30

-0.29 (-0.89%)

04:59
10/21/19
10/21
04:59
10/21/19
04:59
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

APLS

Apellis

$27.78

-0.03 (-0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Apellis participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Dec

FPRX

Five Prime

$3.98

-0.11 (-2.69%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Five Prime management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

ADAP

Adaptimmune

$0.96

-0.035 (-3.54%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Adaptimmune management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ALDR

Alder Biopharmaceuticals

$18.92

0.02 (0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.